Application_NN of_IN the_DT development_NN stages_NNS of_IN a_DT cluster_NN randomized_VBD trial_NN to_TO a_DT framework_NN for_IN evaluating_VBG complex_JJ health_NN interventions_NNS Abstract_NP |_SYM Introduction_NP |_SYM Trials_NN of_IN complex_JJ health_NN interventions_NNS often_RB pose_VBP difficult_JJ methodologic_JJ challenges_NNS ._SENT The_DT objective_NN of_IN this_DT paper_NN is_VBZ to_TO assess_VB the_DT extent_NN to_TO which_WDT the_DT various_JJ development_NN steps_NNS of_IN a_DT cluster_NN randomized_VBD trial_NN to_TO optimize_VB antibiotic_JJ use_NN in_IN nursing_NN homes_NNS are_VBP represented_VBN in_IN a_DT recently_RB published_VBN framework_NN for_IN the_DT design_NN and_CC evaluation_NN of_IN complex_JJ health_NN interventions_NNS ._SENT In_IN so_RB doing_VBG ,_, the_DT utility_NN of_IN the_DT framework_NN for_IN health_NN services_NNS researchers_NNS is_VBZ evaluated_VBN ._SENT Methods_NNS |_SYM Using_VBG the_DT five_CD phases_NNS of_IN the_DT framework_NN (_( theoretical_JJ ,_, identification_NN of_IN components_NNS of_IN the_DT intervention_NN ,_, definition_NN of_IN trial_NN and_CC intervention_NN design_NN ,_, methodological_JJ issues_NNS for_IN main_JJ trial_NN ,_, promoting_VBG effective_JJ implementation_NN )_) ,_, corresponding_JJ stages_NNS in_IN the_DT development_NN of_IN the_DT cluster_NN randomized_VBD trial_NN using_VBG diagnostic_JJ and_CC treatment_NN algorithms_NNS to_TO optimize_VB the_DT use_NN of_IN antibiotics_NNS in_IN nursing_NN homes_NNS are_VBP identified_VBN and_CC described_VBN ._SENT Results_NNS |_SYM Synthesis_NN of_IN evidence_NN needed_VBN to_TO construct_VB the_DT algorithms_NNS ,_, survey_NN and_CC qualitative_JJ research_NN used_VBN to_TO define_VB components_NNS of_IN the_DT algorithms_NNS ,_, a_DT pilot_NN study_NN to_TO assess_VB the_DT feasibility_NN of_IN delivering_VBG the_DT algorithms_NNS ,_, methodological_JJ issues_NNS in_IN the_DT main_JJ trial_NN including_VBG choice_NN of_IN design_NN ,_, allocation_NN concealment_NN ,_, outcomes_NNS ,_, sample_NN size_NN calculation_NN ,_, and_CC analysis_NN are_VBP adequately_RB represented_VBN using_VBG the_DT stages_NNS of_IN the_DT framework_NN ._SENT Conclusions_NNS |_SYM The_DT framework_NN is_VBZ a_DT useful_JJ resource_NN for_IN researchers_NNS planning_VBG a_DT randomized_VBN clinical_JJ trial_NN of_IN a_DT complex_JJ intervention_NN ._SENT Antibiotic_JJ use_NN in_IN nursing_VBG home_NN residents_NNS is_VBZ an_DT important_JJ public_JJ health_NN issue_NN given_VBN that_IN 50_CD %_NN to_TO 75_CD %_NN of_IN residents_NNS are_VBP exposed_VBN to_TO at_IN least_JJS one_CD course_NN of_IN antibiotics_NNS annually_RB ._SENT Such_JJ overuse_NN can_MD potentially_RB lead_VB to_TO the_DT development_NN of_IN multi-drug_NN antibiotic_JJ resistant_JJ bacteria_NNS ,_, drug-related_JJ adverse_JJ effects_NNS ,_, and_CC harmful_JJ drug_NN interactions_NNS ._SENT The_DT appropriate_JJ use_NN of_IN antibiotics_NNS in_IN this_DT setting_NN is_VBZ challenging_VBG ._SENT The_DT diagnosis_NN of_IN infection_NN in_IN residents_NNS of_IN nursing_NN homes_NNS is_VBZ often_RB difficult_JJ ,_, since_IN symptoms_NNS may_MD be_VB vague_JJ and_CC signs_NNS difficult_JJ to_TO elicit_VB ._SENT The_DT evaluation_NN of_IN residents_NNS is_VBZ often_RB made_VBN by_IN nursing_NN staff_NN who_WP have_VBP varying_VBG levels_NNS of_IN expertise_NN and_CC knowledge_NN about_IN infectious_JJ diseases_NNS ._SENT Frequently_RB ,_, treatment_NN decisions_NNS are_VBP made_VBN by_IN busy_JJ clinicians_NNS who_WP rely_VBP on_IN nursing_VBG assessment_NN as_IN their_PP$ primary_JJ source_NN of_IN information_NN ._SENT Interventions_NNS to_TO optimize_VB antibiotic_JJ use_NN in_IN this_DT setting_NN therefore_RB need_VBP to_TO directly_RB involve_VB both_DT nurses_NNS and_CC physicians_NNS and_CC have_VBP the_DT potential_NN for_IN strong_JJ "_`` buy-in_NN "_'' from_IN these_DT healthcare_NN professionals_NNS ._SENT Such_JJ interventions_NNS are_VBP aimed_VBN at_IN changing_VBG behavior_NN and_CC by_IN necessity_NN will_MD involve_VB multiple_JJ components_NNS ._SENT Recently_RB ,_, Campbell_NP and_CC colleagues_NNS published_VBD a_DT framework_NN for_IN the_DT design_NN and_CC evaluation_NN of_IN complex_JJ health_NN interventions_NNS ._SENT Derived_VBN from_IN a_DT document_NN drafted_VBN by_IN members_NNS of_IN the_DT MRC_NP Health_NP Services_NPS and_CC Public_NP Health_NP Research_NP Board_NP ,_, the_DT paper_NN is_VBZ based_VBN on_IN the_DT premise_NN that_IN a_DT different_JJ construct_NN is_VBZ required_VBN for_IN trials_NNS that_WDT evaluate_VBP complex_JJ interventions_NNS ._SENT Examples_NNS include_VBP interventions_NNS to_TO improve_VB delivery_NN of_IN health_NN services_NNS ,_, to_TO change_VB health_NN professionals_NNS '_POS behavior_NN ,_, or_CC to_TO promote_VB health_NN through_IN strategies_NNS aimed_VBN at_IN individuals_NNS ,_, schools_NNS ,_, healthcare_NN facilities_NNS ,_, or_CC communities_NNS ._SENT It_PP is_VBZ apparent_JJ that_IN such_JJ trials_NNS pose_VBP very_RB different_JJ challenges_NNS when_WRB compared_VBN to_TO clinical_JJ trials_NNS designed_VBN ,_, for_IN example_NN ,_, to_TO assess_VB the_DT efficacy_NN of_IN pharmacologic_JJ therapy_NN ._SENT Amongst_IN these_DT are_VBP the_DT development_NN ,_, identification_NN ,_, documentation_NN ,_, and_CC reproduction_NN of_IN the_DT interventions_NNS ._SENT Although_IN such_JJ challenges_NNS are_VBP well_RB known_VBN ,_, few_JJ published_JJ strategies_NNS exist_VBP for_IN researchers_NNS about_RB to_TO embark_VB on_IN a_DT clinical_JJ trial_NN of_IN these_DT interventions_NNS ._SENT Campbell_NP et_FW al._FW propose_VBP that_IN the_DT development_NN and_CC evaluation_NN of_IN such_JJ complex_JJ interventions_NNS be_VB considered_VBN in_IN a_DT series_NN of_IN phases_NNS ,_, analogous_JJ to_TO the_DT sequential_JJ phases_NNS of_IN drug_NN development_NN ._SENT The_DT design_NN and_CC evaluation_NN framework_NN proposed_VBN by_IN Campbell_NP et_FW al._FW appears_VBZ to_TO be_VB well_RB suited_VBN to_TO interventions_NNS for_IN optimizing_VBG antibiotic_JJ use_NN in_IN long-term_JJ care_NN facilities_NNS ._SENT The_DT objective_NN of_IN this_DT paper_NN is_VBZ to_TO evaluate_VB the_DT extent_NN to_TO which_WDT the_DT various_JJ steps_NNS in_IN the_DT development_NN of_IN a_DT cluster_NN randomized_VBD trial_NN to_TO optimize_VB antibiotic_JJ use_NN in_IN nursing_NN homes_NNS are_VBP represented_VBN in_IN the_DT framework_NN for_IN the_DT design_NN and_CC evaluation_NN of_IN complex_JJ health_NN interventions_NNS ._SENT Often_RB it_PP is_VBZ not_RB possible_JJ to_TO evaluate_VB complex_JJ health_NN interventions_NNS ,_, such_JJ as_IN strategies_NNS to_TO improve_VB antibiotic_JJ use_NN in_IN long-term_JJ care_NN facilities_NNS ,_, by_IN randomizing_VBG individuals_NNS ._SENT Cluster_NN randomized_VBD trials_NNS randomize_VB groups_NNS of_IN individuals_NNS ,_, healthcare_NN professionals_NNS ,_, or_CC institutions_NNS ._SENT Applying_VBG the_DT development_NN steps_NNS of_IN this_DT trial_NN to_TO the_DT framework_NN proposed_VBN by_IN Campbell_NP and_CC colleagues_NNS allows_VBZ for_IN a_DT formal_JJ evaluation_NN of_IN the_DT framework_NN 's_POS utility_NN ._SENT The_DT five_CD phases_NNS of_IN the_DT framework_NN of_IN Campbell_NP et_CC al_NP include_VBP 1_CD )_) a_DT pre-clinical_JJ or_CC theoretical_JJ phase_NN ,_, 2_CD )_) Phase_NP I_NP ,_, identification_NN of_IN the_DT components_NNS of_IN the_DT intervention_NN ,_, 3_CD )_) Phase_NP II_NP ,_, definition_NN of_IN the_DT trial_NN and_CC intervention_NN design_NN ,_, 4_CD )_) Phase_NP III_NP ,_, methodological_JJ issues_NNS for_IN the_DT main_JJ trial_NN ,_, and_CC 5_LS )_) Phase_NP IV_NP ,_, promoting_VBG effective_JJ implementation_NN of_IN the_DT intervention_NN ._SENT Using_VBG the_DT framework_NN ,_, the_DT corresponding_JJ stages_NNS of_IN the_DT nursing_NN home_NN trial_NN development_NN are_VBP identified_VBN and_CC described_VBN ._SENT Preclinical_JJ or_CC theoretical_JJ phase_NN |_SYM Overview_NP |_SYM The_DT purpose_NN of_IN this_DT phase_NN is_VBZ to_TO determine_VB if_IN the_DT intervention_NN has_VBZ the_DT potential_JJ to_TO have_VB the_DT desired_VBN effect_NN ._SENT This_DT step_NN can_MD take_VB into_IN account_NN previous_JJ studies_NNS demonstrating_VBG empirical_JJ evidence_NN for_IN the_DT intervention_NN as_RB well_RB as_IN the_DT theoretical_JJ basis_NN for_IN the_DT intervention_NN ._SENT Review_NN of_IN the_DT theoretical_JJ basis_NN for_IN an_DT intervention_NN may_MD lead_VB to_TO an_DT altered_JJ hypothesis_NN and_CC improved_VBN specification_NN of_IN "_`` potentially_RB active_JJ ingredients_NNS "_'' ._SENT The_DT first_JJ step_NN in_IN the_DT development_NN of_IN the_DT algorithms_NNS was_VBD to_TO systematically_RB review_VB the_DT literature_NN for_IN data_NNS that_WDT could_MD lead_VB to_TO strategies_NNS for_IN reducing_VBG antibiotic_JJ use_NN ._SENT Lower_JJR respiratory_JJ infections_NNS ,_, urinary_JJ infections_NNS ,_, and_CC skin_NN and_CC soft_JJ tissue_NN infections_NNS account_VBP for_IN the_DT majority_NN of_IN bacterial_JJ infections_NNS in_IN residents_NNS of_IN long-term_JJ care_NN facilities_NNS ._SENT No_DT data_NNS to_TO support_VB reducing_VBG antibiotics_NNS for_IN lower_JJR respiratory_JJ or_CC skin_NN infections_NNS was_VBD located_VBN ._SENT In_IN contrast_NN ,_, data_NNS to_TO support_VB reducing_VBG antibiotic_JJ use_NN for_IN urinary_JJ indications_NNS was_VBD found_VBN ._SENT Asymptomatic_JJ bacteriuria_NNS ,_, the_DT presence_NN of_IN bacteria_NNS in_IN the_DT urine_NN in_IN the_DT absence_NN of_IN urinary_JJ symptoms_NNS ,_, occurs_VBZ in_IN up_IN to_TO 50_CD %_NN of_IN older_JJR institutionalized_VBN women_NNS and_CC 35_CD %_NN of_IN institutionalized_VBD older_JJR men_NNS ._SENT There_EX are_VBP four_CD randomized_VBD controlled_JJ trials_NNS that_WDT demonstrate_VBP no_DT benefit_NN in_IN treating_VBG asymptomatic_JJ bacteriuria_NNS in_IN residents_NNS of_IN long-term_JJ care_NN facilities_NNS ._SENT Despite_IN the_DT evidence_NN ,_, one_CD third_NN of_IN all_DT prescriptions_NNS for_IN urinary_JJ indications_NNS in_IN residents_NNS of_IN nursing_NN homes_NNS are_VBP for_IN asymptomatic_JJ bacteriuria_NNS ._SENT Accordingly_RB ,_, the_DT algorithms_NNS indicate_VBP that_IN urine_NN should_MD not_RB be_VB cultured_VBN and_CC antibiotics_NNS should_MD not_RB be_VB prescribed_VBN in_IN the_DT absence_NN of_IN clinical_JJ features_NNS of_IN urinary_JJ infection_NN (_( Figures_NNS and_CC )_) ._SENT The_DT algorithms_NNS also_RB consider_VBP the_DT increased_VBN risk_NN of_IN urinary_JJ infection_NN with_IN indwelling_VBG urinary_JJ catheters_NNS and_CC with_IN specific_JJ urinary_JJ symptoms_NNS ._SENT Figure_NP 1_CD |_SYM Diagnostic_JJ algorithm_NN ._SENT Diagnostic_JJ algorithm_NN ._SENT This_DT algorithm_NN guides_VBZ physicians_NNS and_CC nurses_NNS in_IN the_DT ordering_VBG of_IN urine_NN cultures_NNS for_IN nursing_VBG home_NN residents_NNS with_IN suspected_JJ infections_NNS ._SENT Figure_NP 2_CD |_SYM Treatment_NP algorithm_NN ._SENT Treatment_NN algorithm_NN ._SENT This_DT algorithm_NN allows_VBZ physicians_NNS and_CC nurses_NNS to_TO optimize_VB antibiotic_JJ use_NN in_IN residents_NNS with_IN suspected_JJ infections_NNS ._SENT Phase_VB I_PP :_: defining_VBG components_NNS of_IN the_DT intervention_NN |_SYM Overview_NP |_SYM This_DT phase_NN ,_, often_RB inter-related_JJ to_TO the_DT previous_JJ phase_NN ,_, emphasizes_VBZ modeling_NN or_CC simulation_NN studies_NNS to_TO improve_VB understanding_NN of_IN the_DT components_NNS of_IN an_DT intervention_NN ._SENT Use_NN of_IN qualitative_JJ research_NN and_CC descriptive_JJ studies_NNS may_MD help_VB define_VB components_NNS of_IN the_DT intervention_NN ._SENT Furthermore_RB ,_, in_IN this_DT phase_NN potential_JJ barriers_NNS in_IN trials_NNS that_WDT seek_VBP to_TO change_VB behavior_NN may_MD be_VB elicited_VBN ._SENT In_IN order_NN to_TO assess_VB the_DT potential_JJ effectiveness_NN of_IN the_DT two_CD algorithms_NNS ,_, we_PP applied_VBD them_PP to_TO data_NNS from_IN a_DT study_NN assessing_VBG antibiotic_JJ use_NN in_IN Ontario_NP chronic_JJ care_NN facilities_NNS ._SENT In_IN this_DT modeling_NN exercise_NN ,_, we_PP found_VBD that_IN the_DT algorithms_NNS could_MD reduce_VB antibiotic_JJ use_NN for_IN urinary_JJ indications_NNS by_IN 80_CD %_NN ._SENT Previously_RB ,_, we_PP had_VBD conducted_VBN focus_NN groups_NNS among_IN physicians_NNS and_CC nurses_NNS who_WP provide_VBP care_NN to_TO nursing_VBG home_NN residents_NNS ._SENT Our_PP$ objective_NN was_VBD to_TO explore_VB the_DT perceptions_NNS ,_, attitudes_NNS ,_, and_CC opinions_NNS of_IN those_DT involved_VBN in_IN the_DT process_NN of_IN prescribing_VBG antibiotics_NNS for_IN asymptomatic_JJ bacteriuria_NNS ._SENT Twenty-two_NN physicians_NNS and_CC 16_CD nurses_NNS ,_, each_DT in_IN two_CD focus_NN groups_NNS ,_, participated_VBD ._SENT Both_DT physicians_NNS and_CC nurses_NNS emphasized_VBD that_IN there_EX was_VBD a_DT wide_JJ range_NN of_IN indicators_NNS ,_, more_RBR subtle_JJ than_IN the_DT classic_JJ symptoms_NNS of_IN urinary_JJ tract_NN infection_NN ,_, that_WDT influence_VBP the_DT ordering_VBG of_IN cultures_NNS and_CC the_DT prescribing_VBG of_IN antibiotics_NNS ._SENT Because_IN residents_NNS in_IN long-term_JJ care_NN facilities_NNS frequently_RB have_VBP cognitive_JJ impairment_NN and_CC are_VBP unable_JJ to_TO articulate_VB their_PP$ symptoms_NNS ,_, health_NN care_NN providers_NNS rely_VBP instead_RB on_IN signs_NNS of_IN more_JJR subtle_JJ functional_JJ and_CC behavioural_JJ changes_NNS ._SENT Misconceptions_NNS about_IN the_DT definition_NN of_IN symptoms_NNS of_IN urinary_JJ tract_NN infection_NN were_VBD also_RB discussed_VBN ._SENT Although_IN the_DT nurses_NNS participating_VBG in_IN the_DT focus_NN groups_NNS had_VBD learned_VBN that_IN foul-smelling_VBG urine_NN alone_RB was_VBD not_RB sufficient_JJ reason_NN to_TO order_VB a_DT culture_NN ,_, a_DT number_NN of_IN physicians_NNS still_RB felt_VBD that_IN this_DT was_VBD one_CD of_IN the_DT main_JJ reasons_NNS why_WRB cultures_NNS are_VBP ordered_VBN ._SENT Other_JJ key_JJ findings_NNS included_VBD the_DT influence_NN nurses_NNS have_VBP over_IN physician_NN prescribing_VBG through_IN their_PP$ description_NN of_IN the_DT clinical_JJ situation_NN ,_, often_RB conveyed_VBD over_IN the_DT telephone_NN ._SENT Physicians_NNS attributed_VBD their_PP$ use_NN of_IN antibiotics_NNS to_TO treat_VB bacteriuria_NNS in_IN residents_NNS with_IN no_DT urinary_JJ symptoms_NNS to_TO relatively_RB vague_JJ non-urinary_JJ symptoms_NNS (_( e.g._FW lethargy_NN ,_, change_NN in_IN functional_JJ status_NN )_) ._SENT To_TO these_DT physicians_NNS ,_, this_DT meant_VBD that_IN such_JJ residents_NNS were_VBD not_RB in_IN fact_NN "_`` asymptomatic_JJ "_'' ,_, despite_IN the_DT fact_NN that_IN absence_NN of_IN urinary_JJ symptoms_NNS alone_RB was_VBD used_VBN to_TO define_VB asymptomatic_JJ bacteriuria_NNS in_IN the_DT clinical_JJ trials_NNS ._SENT This_DT was_VBD an_DT important_JJ barrier_NN to_TO evidence-based_JJ care_NN that_WDT would_MD not_RB have_VB been_VBN discovered_VBN without_IN using_VBG a_DT qualitative_JJ approach_NN ._SENT To_TO assess_VB the_DT factors_NNS leading_VBG to_TO the_DT ordering_VBG of_IN urine_NN cultures_NNS ,_, we_PP conducted_VBD a_DT prospective_JJ survey_NN in_IN four_CD nursing_NN homes_NNS ._SENT Nursing_NN staff_NN were_VBD asked_VBN to_TO complete_VB a_DT brief_JJ questionnaire_NN every_DT time_NN a_DT request_NN for_IN a_DT urine_NN culture_NN was_VBD made_VBN ._SENT They_PP were_VBD asked_VBN to_TO specify_VB the_DT signs_NNS and_CC symptoms_NNS present_JJ at_IN the_DT time_NN the_DT culture_NN was_VBD ordered_VBN and_CC to_TO specify_VB who_WP initiated_VBD the_DT request_NN for_IN the_DT culture_NN ._SENT Physicians_NNS ,_, after_IN they_PP received_VBD the_DT results_NNS of_IN the_DT urine_NN culture_NN ,_, were_VBD asked_VBN to_TO indicate_VB the_DT clinical_JJ reasons_NNS for_IN their_PP$ therapeutic_JJ decision_NN ._SENT Forty-eight_NN percent_NN of_IN the_DT 545_CD urine_NN cultures_NNS obtained_VBN over_IN six_CD months_NNS were_VBD ordered_VBN by_IN nursing_VBG staff_NN and_CC 52_CD %_NN by_IN physicians_NNS ._SENT The_DT urine_NN culture_NN was_VBD suggested_VBN by_IN nursing_NN staff_NN 56_CD %_NN of_IN the_DT time_NN ._SENT For_IN 67_CD %_NN of_IN urine_NN culture_NN orders_NNS ,_, there_EX were_VBD no_DT urinary_JJ symptoms_NNS present_JJ at_IN the_DT time_NN the_DT culture_NN was_VBD requested_VBN ._SENT One_CD in_IN every_DT three_CD urine_NN cultures_NNS ordered_VBD resulted_VBN in_IN an_DT antibiotic_JJ prescription_NN ._SENT Of_IN these_DT prescriptions_NNS ,_, one_CD third_NN were_VBD for_IN asymptomatic_JJ bacteriuria_NNS ._SENT Phase_NN II_NP :_: defining_VBG trial_NN and_CC intervention_NN design_NN |_SYM Overview_NP |_SYM In_IN this_DT phase_NN ,_, the_DT information_NN gathered_VBN in_IN phase_NN I_PP is_VBZ used_VBN to_TO develop_VB the_DT optimum_JJ intervention_NN and_CC study_NN design_NN ._SENT The_DT feasibility_NN of_IN delivering_VBG the_DT intervention_NN is_VBZ tested_VBN and_CC the_DT acceptability_NN to_TO healthcare_NN providers_NNS and_CC patients_NNS is_VBZ assessed_VBN ._SENT The_DT diagnostic_JJ and_CC treatment_NN algorithms_NNS were_VBD tested_VBN and_CC further_RBR refined_JJ in_IN a_DT three-month_JJ pilot_NN study_NN conducted_VBN in_IN four_CD nursing_NN homes_NNS ._SENT Administrators_NNS and_CC directors_NNS of_IN nursing_NN of_IN the_DT homes_NNS felt_VBD that_IN the_DT algorithms_NNS should_MD be_VB introduced_VBN to_TO the_DT nursing_NN staff_NN by_IN each_DT facility_NN 's_POS infection_NN control_NN practitioner_NN ._SENT To_TO ensure_VB that_IN the_DT infection_NN control_NN practitioners_NNS themselves_PP understood_VBD the_DT algorithms_NNS ,_, they_PP were_VBD asked_VBN to_TO decide_VB whether_IN urine_NN cultures_NNS should_MD be_VB obtained_VBN and_CC antibiotics_NNS ordered_VBN for_IN six_CD case-scenarios_NNS using_VBG the_DT algorithms_NNS ._SENT Using_VBG this_DT "_`` train_VB the_DT trainer_NN "_`` approach_NN ,_, the_DT practitioners_NNS then_RB conducted_VBN brief_JJ seminars_NNS with_IN registered_JJ nursing_NN staff_NN to_TO introduce_VB the_DT algorithms_NNS in_IN their_PP$ facilities_NNS ._SENT This_DT approach_NN was_VBD unsuccessful_JJ however_RB ._SENT Semi-structured_JJ interviews_NNS with_IN staff_NN revealed_VBD that_IN in_IN two_CD of_IN the_DT homes_NNS there_EX were_VBD nurses_NNS who_WP were_VBD completely_RB unfamiliar_JJ with_IN the_DT algorithms_NNS two-thirds_NNS of_IN the_DT way_NN into_IN the_DT pilot_NN study_NN ._SENT This_DT led_VBD to_TO the_DT development_NN of_IN a_DT standardized_JJ 30-minute_JJ presentation_NN of_IN six_CD case-scenarios_NNS facilitated_VBN by_IN one_CD of_IN two_CD study_NN investigators_NNS ._SENT Participation_NN was_VBD active_JJ ,_, staff_NN were_VBD asked_VBN to_TO decide_VB whether_IN to_TO order_VB antibiotics_NNS and_CC urine_NN cultures_NNS and_CC to_TO justify_VB their_PP$ answers_NNS using_VBG the_DT algorithms_NNS ._SENT In_IN addition_NN ,_, a_DT video-tape_NN replicating_VBG the_DT seminar_NN material_NN was_VBD made_VBN and_CC distributed_VBN to_TO the_DT nursing_NN homes_NNS ._SENT The_DT use_NN of_IN logs_NNS to_TO document_VB appropriate_JJ adherence_NN to_TO the_DT algorithms_NNS was_VBD also_RB piloted_VBN during_IN the_DT three-month_JJ pilot_NN ._SENT Office_NN visits_NNS to_TO introduce_VB the_DT algorithms_NNS to_TO nursing_NN home_NN physicians_NNS were_VBD conducted_VBN using_VBG the_DT six_CD case-scenarios_NNS presented_VBN to_TO nursing_NN staff_NN ._SENT Feedback_NN about_IN the_DT algorithms_NNS from_IN both_DT physicians_NNS and_CC nurses_NNS was_VBD positive_JJ ,_, both_CC groups_NNS felt_VBD that_IN the_DT algorithms_NNS were_VBD user_NN friendly_JJ and_CC feasible_JJ in_IN the_DT long-term_JJ care_NN setting_NN ._SENT Additionally_RB ,_, the_DT initial_JJ poor_JJ adherence_NN to_TO the_DT algorithms_NNS indicated_VBD that_IN regularly_RB scheduled_VBN on-site_JJ visits_NNS should_MD be_VB another_DT component_NN of_IN the_DT intervention_NN ,_, serving_VBG as_IN an_DT important_JJ reminder_NN or_CC cue_NN to_TO the_DT participants_NNS ._SENT Meetings_NNS with_IN the_DT local_JJ champion_NN for_IN the_DT study_NN (_( usually_RB the_DT director_NN of_IN nursing_NN )_) to_TO discuss_VB barriers_NNS or_CC obstacles_NNS to_TO completing_VBG the_DT study_NN were_VBD therefore_RB held_VBN during_IN the_DT pilot_NN ._SENT Feedback_NN about_IN adherence_NN to_TO the_DT protocol_NN was_VBD given_VBN ._SENT Such_JJ follow_VBP up_RP visits_NNS were_VBD acceptable_JJ to_TO staff_NN and_CC administrators_NNS as_IN they_PP were_VBD not_RB overly_RB time_NN consuming_NN ._SENT Phase_NN III_NP :_: methodological_JJ issues_NNS for_IN the_DT main_JJ trial_NN |_SYM Overview_NP |_SYM Campbell_NP and_CC colleagues_NNS state_VBP that_IN this_DT step_NN addresses_VBZ issues_NNS normally_RB posed_VBN by_IN randomized_VBN trials_NNS ,_, such_JJ as_IN sample_NN size_NN ,_, inclusion_NN and_CC exclusion_NN criteria_NNS ,_, methods_NNS of_IN randomization_NN ,_, as_RB well_RB as_IN the_DT challenges_NNS of_IN complex_JJ interventions_NNS ._SENT The_DT main_JJ antibiotic_JJ trial_NN uses_VBZ a_DT randomized_VBN matched_VBN pair_NN design_NN where_WRB one_CD of_IN 11_CD pairs_NNS of_IN nursing_NN homes_NNS (_( matched_VBN by_IN size_NN and_CC case-mix_NN )_) ,_, has_VBZ been_VBN randomized_VBN to_TO the_DT clinical_JJ algorithms_NNS and_CC the_DT other_JJ to_TO usual_JJ management_NN of_IN presumptive_JJ urinary_JJ tract_NN infections_NNS ._SENT Only_RB free-standing_JJ ,_, community-based_JJ nursing_NN homes_NNS are_VBP eligible_JJ i.e._FW those_DT representative_NN of_IN the_DT majority_NN of_IN nursing_VBG homes_NNS in_IN Canada_NP and_CC the_DT United_NP States_NPS ._SENT To_TO be_VB eligible_JJ ,_, nursing_NN homes_NNS must_MD also_RB :_: 1_LS )_) have_VBP 100_CD or_CC more_JJR residents_NNS (_( since_IN the_DT required_JJ sample_NN size_NN of_IN antibiotics_NNS courses_NNS will_MD be_VB achieved_VBN sooner_RBR )_) ;_: 2_LS )_) have_VBP no_RB stated_VBN policy_NN for_IN diagnosis_NN or_CC treatment_NN of_IN urinary_JJ tract_NN infections_NNS ;_: 3_LS )_) agree_VB to_TO refrain_VB from_IN introducing_VBG new_JJ management_NN strategies_NNS for_IN antibiotic_JJ utilization_NN or_CC urinary_JJ tract_NN infection_NN during_IN the_DT study_NN ._SENT The_DT primary_JJ outcome_NN of_IN this_DT trial_NN is_VBZ the_DT total_JJ number_NN of_IN antibiotic_JJ courses_NNS prescribed_VBN ._SENT Other_JJ outcomes_NNS include_VBP 1_CD )_) the_DT proportion_NN of_IN antibiotic_JJ courses_NNS prescribed_VBN for_IN urinary_JJ indications_NNS ,_, 2_LS )_) rates_NNS of_IN urine_NN cultures_NNS ordered_VBD ,_, 3_CD )_) hospitalization_NN rates_NNS for_IN urinary_JJ tract_NN infections_NNS ,_, and_CC 4_LS )_) mortality_NN rates_NNS ._SENT The_DT last_JJ two_CD outcomes_NNS are_VBP being_VBG measured_VBN to_TO ensure_VB that_IN the_DT algorithms_NNS can_MD safely_RB be_VB applied_VBN ._SENT Within_IN a_DT nursing_NN home_NN ,_, randomization_NN of_IN individual_JJ healthcare_NN providers_NNS to_TO the_DT algorithm_NN likely_RB would_MD introduce_VB bias_NN due_JJ to_TO contamination_NN ._SENT Therefore_RB ,_, for_IN the_DT quantitative_JJ component_NN of_IN this_DT study_NN ,_, the_DT nursing_NN home_NN will_MD serve_VB as_IN the_DT unit_NN of_IN allocation_NN and_CC analysis_NN ._SENT To_TO conceal_VB allocation_NN ,_, one_CD nursing_NN home_NN in_IN each_DT pair_NN was_VBD arbitrarily_RB assigned_VBN an_DT even_JJ number_NN (_( and_CC the_DT other_JJ odd_NN )_) by_IN a_DT hospital_NN administrative_JJ assistant_NN not_RB associated_VBN with_IN the_DT study_NN or_CC any_DT of_IN the_DT investigators_NNS and_CC who_WP was_VBD blinded_VBN to_TO the_DT nursing_NN homes_NNS '_POS identity_NN ._SENT A_DT statistician_NN who_WP is_VBZ not_RB associated_VBN with_IN the_DT study_NN and_CC who_WP was_VBD unaware_JJ of_IN the_DT nursing_NN home_NN pairs_NNS ,_, generated_VBD a_DT list_NN of_IN 11_CD random_JJ numbers_NNS using_VBG a_DT random_JJ numbers_NNS table_NN ,_, one_CD for_IN each_DT pair_NN of_IN nursing_NN homes_NNS ._SENT The_DT corresponding_JJ odd_JJ or_CC even_RB numbered_VBD nursing_VBG home_NN in_IN each_DT pair_NN was_VBD assigned_VBN the_DT intervention_NN ._SENT An_DT absolute_JJ reduction_NN in_IN 20_CD %_NN of_IN all_DT antibiotic_JJ use_NN ,_, which_WDT corresponds_VBZ to_TO a_DT reduction_NN in_IN the_DT proportion_NN of_IN antibiotic_JJ prescriptions_NNS for_IN urinary_JJ indications_NNS from_IN 30_CD %_NN to_TO 10_CD %_NN ,_, was_VBD considered_VBN the_DT minimal_JJ clinically_RB important_JJ effect_NN worth_NN detecting_VBG ._SENT To_TO detect_VB this_DT difference_NN ,_, for_IN an_DT alpha_NN of_IN 0.05_CD and_CC 80_CD %_NN power_NN ,_, adjusting_VBG for_IN the_DT effect_NN of_IN within_IN cluster_NN dependency_NN ,_, 4513_CD prescriptions_NNS need_VBP to_TO be_VB collected_VBN in_IN total_NN ._SENT This_DT means_VBZ that_IN 20_CD or_CC 10_CD pairs_NNS of_IN nursing_NN homes_NNS will_MD need_VB to_TO be_VB followed_VBN for_IN 10_CD months_NNS ._SENT Given_VBN the_DT potential_NN for_IN withdrawals_NNS of_IN nursing_NN homes_NNS ,_, 22_CD homes_NNS will_MD be_VB recruited_VBN ._SENT A_DT paired_VBN t-test_NN will_MD be_VB used_VBN to_TO analyse_VB the_DT within-pair_JJ differences_NNS between_IN the_DT proportions_NNS of_IN antibiotics_NNS prescribed_VBN for_IN urinary_JJ indications_NNS in_IN matched_VBN pairs_NNS of_IN nursing_NN homes_NNS ._SENT This_DT way_NN ,_, the_DT fact_NN that_IN the_DT denominator_NN of_IN the_DT proportions_NNS is_VBZ actually_RB an_DT outcome_NN is_VBZ taken_VBN into_IN consideration_NN ._SENT Differences_NNS in_IN rates_NNS of_IN overall_JJ antibiotic_JJ use_NN (_( antibiotic_JJ courses_NNS per_IN 1000_CD resident_JJ days_NNS )_) will_MD be_VB compared_VBN using_VBG a_DT paired_VBN t-test_NN ._SENT Rates_NNS of_IN antibiotic_JJ use_NN for_IN urinary_JJ indications_NNS (_( antibiotic_JJ courses_NNS per_IN 1000_CD resident_JJ days_NNS and_CC defined_VBN daily_JJ dosages/1000_NN resident_NN days_NNS )_) ,_, rates_NNS of_IN urine_NN cultures_NNS obtained_VBN (_( urine_NN cultures_NNS per_IN 1000_CD resident_JJ days_NNS )_) ,_, rates_NNS of_IN hospitalization_NN (_( per_IN 1000_CD resident_JJ days_NNS )_) ,_, and_CC overall_JJ mortality_NN rates_NNS will_MD be_VB compared_VBN using_VBG paired_VBN t-tests_NNS and_CC Wilcoxon_NP signed_VBD rank_JJ test_NN ._SENT Logistic_JJ regression_NN analysis_NN that_WDT adjusts_VBZ for_IN the_DT effect_NN of_IN clustering_VBG will_MD be_VB performed_VBN to_TO adjust_VB for_IN potentially_RB important_JJ co-variates_NNS such_JJ as_IN nursing_VBG home_NN size_NN ,_, proportion_NN of_IN residents_NNS bed/wheelchair_NN bound_VBN ,_, and_CC pharmacy_NN automatic_JJ stop_NN dates_NNS ._SENT Phase_NN IV_CD :_: promoting_VBG effective_JJ stability_NN of_IN the_DT intervention_NN ,_, assessing_VBG for_IN the_DT existence_NN of_IN adverse_JJ effects_NNS |_SYM Qualitative_JJ studies_NNS to_TO assess_VB the_DT attitudes_NNS and_CC perceptions_NNS of_IN both_DT nurses_NNS and_CC physicians_NNS will_MD help_VB us_PP understand_VB the_DT key_JJ elements_NNS to_TO maintaining_VBG sustainability_NN should_MD the_DT intervention_NN prove_VB to_TO be_VB successful_JJ in_IN reducing_VBG antibiotic_JJ use_NN ._SENT We_PP plan_VBP to_TO conduct_VB focus_NN group_NN studies_NNS for_IN nursing_VBG staff_NN and_CC semi-structured_JJ interviews_NNS amongst_IN physicians_NNS and_CC directors_NNS of_IN nursing_NN care_NN ._SENT If_IN the_DT intervention_NN is_VBZ not_RB successful_JJ ,_, this_DT qualitative_JJ approach_NN may_MD help_VB explain_VB the_DT barriers_NNS leading_VBG to_TO failure_NN of_IN the_DT intervention_NN ._SENT Although_IN the_DT trial_NN itself_PP is_VBZ meant_VBN to_TO examine_VB the_DT effectiveness_NN of_IN the_DT intervention_NN ,_, including_VBG adherence_NN and_CC adverse_JJ effects_NNS ,_, if_IN the_DT results_NNS demonstrate_VBP that_IN the_DT intervention_NN can_MD reduce_VB overall_JJ antibiotic_JJ use_NN and_CC is_VBZ safe_JJ ,_, one_CD possibility_NN is_VBZ to_TO conduct_VB a_DT cohort_NN study_NN of_IN the_DT algorithms_NNS in_IN nursing_VBG homes_NNS over_IN a_DT large_JJ geographic_JJ area_NN will_MD be_VB made_VBN ._SENT The_DT application_NN of_IN the_DT trial_NN to_TO improve_VB antibiotic_JJ use_NN in_IN nursing_VBG home_NN residents_NNS to_TO the_DT framework_NN demonstrates_VBZ that_IN the_DT framework_NN is_VBZ a_DT useful_JJ resource_NN for_IN health_NN services_NNS researchers_NNS ._SENT Not_RB surprisingly_RB ,_, the_DT stages_NNS of_IN the_DT framework_NN have_VBP been_VBN used_VBN in_IN previous_JJ studies_NNS of_IN complex_JJ interventions_NNS ,_, even_RB before_IN the_DT framework_NN was_VBD published_VBN ._SENT One_CD recent_JJ example_NN is_VBZ the_DT Rapid_NP Early_NP Action_NP for_IN Coronary_NP Treatment_NP (_( REACT_NP )_) ,_, a_DT multi-component_JJ ,_, community-based_JJ educational_JJ intervention_NN of_IN community_NN development_NN ,_, public_JJ education_NN ,_, provider_NN education_NN ,_, and_CC patient_JJ education_NN (_( 31_CD )_) ._SENT The_DT description_NN of_IN the_DT trial_NN described_VBN in_IN this_DT paper_NN however_RB allows_VBZ for_IN a_DT focused_VBN assessment_NN of_IN the_DT components_NNS of_IN this_DT framework_NN ._SENT The_DT pre-clinical_JJ phase_NN of_IN the_DT antibiotic_JJ trial_NN involved_VBD a_DT summary_NN of_IN the_DT evidence_NN needed_VBD to_TO construct_VB the_DT algorithms_NNS ._SENT This_DT phase_NN should_MD include_VB a_DT systematic_JJ review_NN of_IN the_DT literature_NN with_IN respect_NN to_TO the_DT intervention_NN ,_, a_DT point_NN omitted_VBN in_IN the_DT pre-clinical_JJ phase_NN description_NN of_IN the_DT design_NN paper_NN but_CC discussed_VBN in_IN the_DT Medical_NP Research_NP Council_NP paper_NN described_VBD in_IN the_DT text_NN ._SENT It_PP was_VBD also_RB evident_JJ that_IN the_DT preclinical_JJ and_CC first_JJ phase_NN cannot_MD be_VB clearly_RB demarcated_VBN ,_, given_VBN that_IN it_PP was_VBD the_DT modeling_VBG study_NN in_IN phase_NN I_PP which_WDT actually_RB determined_VBD if_IN the_DT intervention_NN had_VBD the_DT potential_JJ to_TO have_VB the_DT desired_VBN effect_NN ,_, the_DT stated_JJ aim_NN of_IN the_DT preclinical_JJ phase_NN ._SENT The_DT use_NN of_IN qualitative_JJ research_NN to_TO help_VB define_VB the_DT intervention_NN was_VBD extremely_RB valuable_JJ ._SENT Focus_NN group_NN studies_NNS helped_VBD to_TO accurately_RB identify_VB and_CC anticipate_VB barriers_NNS to_TO the_DT intervention_NN ,_, even_RB prior_RB to_TO the_DT pilot_NN study_NN ._SENT Determining_VBG physicians_NNS and_CC nurses_NNS attitudes_NNS ,_, beliefs_NNS ,_, and_CC behaviors_NNS toward_IN antibiotic_JJ use_NN for_IN urinary_JJ infections_NNS highlighted_VBD the_DT importance_NN of_IN nonspecific_JJ ,_, non-urinary_JJ symptoms_NNS and_CC the_DT key_JJ role_NN of_IN nurses_NNS in_IN the_DT process_NN of_IN antibiotic_JJ treatment_NN of_IN asymptomatic_JJ bacteriuria_NNS in_RB institutionalized_VBD older_JJR adults_NNS ._SENT As_IN specified_VBN in_IN the_DT framework_NN ,_, these_DT findings_NNS illustrate_VBP the_DT utility_NN of_IN using_VBG qualitative_JJ methods_NNS early_JJ in_IN the_DT development_NN of_IN complex_JJ interventions_NNS ._SENT Focus_NN groups_NNS and_CC semi-structured_JJ interviews_NNS will_MD also_RB be_VB conducted_VBN at_IN the_DT end_NN of_IN the_DT main_JJ trial_NN ._SENT We_PP anticipate_VBP that_IN such_JJ qualitative_JJ data_NNS will_MD help_VB us_PP identify_VB strategies_NNS to_TO sustain_VB the_DT algorithms_NNS should_MD the_DT algorithms_NNS prove_VBP to_TO be_VB effective_JJ in_IN reducing_VBG antibiotic_JJ use_NN ._SENT Results_NNS of_IN the_DT questionnaires_NNS administered_VBN to_TO nurses_NNS and_CC physicians_NNS used_VBN in_IN developing_VBG the_DT algorithms_NNS provided_VBD convincing_JJ evidence_NN about_IN the_DT need_NN to_TO target_VB both_DT ordering_VBG of_IN urine_NN cultures_NNS and_CC antibiotic_JJ prescribing_VBG in_IN order_NN to_TO reduce_VB overall_JJ antibiotic_JJ use_NN ._SENT The_DT particular_JJ importance_NN of_IN introducing_VBG the_DT algorithms_NNS to_TO nurses_NNS in_IN order_NN to_TO culturing_VBG of_IN urine_NN was_VBD emphasized_VBN ._SENT This_DT confirmed_VBD the_DT qualitative_JJ findings_NNS ._SENT It_PP is_VBZ notable_JJ that_IN although_IN the_DT phases_NNS of_IN the_DT framework_NN are_VBP described_VBN as_IN being_VBG sequential_JJ ,_, components_NNS of_IN the_DT frameworks_NNS might_MD vary_VB temporally_RB ,_, as_IN exemplified_VBN by_IN the_DT qualitative_JJ and_CC questionnaire_NN data_NNS described_VBN in_IN phase_NN I_PP being_VBG collected_VBN prior_RB to_TO the_DT actual_JJ development_NN of_IN the_DT algorithms_NNS ._SENT The_DT pilot_NN study_NN was_VBD instrumental_JJ in_IN refining_VBG and_CC introducing_VBG the_DT algorithms_NNS ._SENT One_CD of_IN the_DT most_RBS valuable_JJ aspects_NNS of_IN the_DT pilot_NN study_NN was_VBD finding_VBG the_DT optimal_JJ way_NN to_TO introduce_VB the_DT algorithms_NNS to_TO nurses_NNS and_CC physicians_NNS ._SENT Perhaps_RB more_JJR emphasis_NN could_MD have_VB been_VBN placed_VBN on_IN strategies_NNS to_TO introduce_VB the_DT complex_JJ health_NN interventions_NNS in_IN the_DT design_NN framework_NN ._SENT An_DT important_JJ methodological_JJ issue_NN for_IN randomized_VBN trials_NNS of_IN complex_JJ health_NN interventions_NNS is_VBZ allocation_NN concealment_NN ._SENT This_DT was_VBD a_DT key_JJ consideration_NN in_IN the_DT design_NN and_CC implementation_NN of_IN the_DT antibiotic_JJ trial_NN ._SENT Empiric_JJ evidence_NN exists_VBZ to_TO suggest_VB that_DT failure_NN to_TO conceal_VB allocation_NN can_MD result_VB in_IN larger_JJR biased_VBN estimates_NNS of_IN effect_NN than_IN failure_NN to_TO blind_VB ._SENT When_WRB a_DT limited_JJ number_NN of_IN clusters_NNS are_VBP randomized_VBN ,_, such_JJ as_IN in_IN this_DT trial_NN ,_, there_EX is_VBZ extra_JJ concern_NN ._SENT Although_IN it_PP is_VBZ often_RB impossible_JJ to_TO blind_JJ patients_NNS ,_, practitioners_NNS ,_, and_CC researchers_NNS to_TO the_DT intervention_NN ,_, it_PP is_VBZ always_RB possible_JJ to_TO conceal_VB allocation_NN ._SENT Such_JJ issues_NNS are_VBP well_RB described_VBN in_IN the_DT Medical_NP Research_NP Council_NP paper_NN described_VBD in_IN the_DT text_NN ._SENT Sample_NN size_NN calculation_NN is_VBZ an_DT important_JJ challenge_NN in_IN cluster-randomized_JJ trials_NNS ._SENT Cluster_NN randomization_NN reduces_VBZ power_NN and_CC the_DT sample_NN size_NN generally_RB needs_VBZ to_TO be_VB substantially_RB increased_VBN ._SENT Further_JJR elaboration_NN on_IN this_DT topic_NN in_IN the_DT Phase_NP III_NP of_IN the_DT framework_NN would_MD be_VB of_IN benefit_NN to_TO researchers_NNS ._SENT The_DT application_NN of_IN a_DT randomized_VBN trial_NN to_TO optimize_VB antibiotic_JJ use_NN in_IN nursing_VBG homes_NNS to_TO the_DT framework_NN reported_VBD by_IN Campbell_NP and_CC colleagues_NNS demonstrated_VBD that_IN the_DT framework_NN is_VBZ a_DT useful_JJ resource_NN for_IN researchers_NNS embarking_VBG on_IN a_DT clinical_JJ trial_NN of_IN a_DT complex_JJ health_NN intervention_NN ._SENT None_NN declared_VBD ._SENT publication_NN history_NN :_: The_DT pre-publication_NN history_NN for_IN this_DT paper_NN can_MD be_VB accessed_VBN here_RB :_: 